Immunogenicity of a mucosal vaccine against SARS-CoV2 responsible for covid-19

Google translate: With the current pandemic and the urgency of finding effective treatments to control the progression of the disease, a race has begun to develop an effective vaccine against the virus responsible for Covid-19. Although the development of a vaccine takes a long time, the fact remains that vaccination remains the best means of protecting the population in the medium and long term and curbing the resurgence of the disease. Several approaches are proposed for the development of this vaccine, each with its advantages and disadvantages. However, the multitude of proposed approaches will ensure that a vaccine candidate will eventually give convincing results. This project aims to demonstrate the concept of one of these vaccine approaches. The project proposes to use probiotic bacteria modified to express the major protein of the virus in order to use them as immunization vectors through the oral or nasal mucous membranes. This approach, which has already been used experimentally to design other vaccines, offers the advantage of creating immunity at the main entry point of the virus: the respiratory tract. this approach should facilitate their registration with regulatory agencies. If they prove conclusive, the results of this preliminary study open the door to efficacy studies and the continuation of this approach in order to come up with a solution to control this infection.]